What is Delcath Systems?
Founded in 1988 and headquartered in New York, Delcath Systems operates as a specialized medical technology firm focused on the development of interventional oncology solutions. Its core asset, the Delcath hepatic delivery system, is engineered to administer high-dose chemotherapy directly to the liver, a critical advancement for patients suffering from primary and metastatic liver malignancies. By isolating the liver from the systemic circulation, the company's technology aims to maximize therapeutic efficacy while minimizing the systemic toxicity typically associated with traditional chemotherapy. This unique market position allows Delcath to address significant unmet needs in the oncology landscape, particularly for patients with limited treatment options.
How much funding has Delcath Systems raised?
Delcath Systems has raised a total of $108.5M across 3 funding rounds:
Stock Offering
$7.2M
Other Financing Round
$85M
Series E
$16.3M
Stock Issuance/Offering (2000): $7.2M, investors not publicly disclosed
Other Financing Round (2023): $85M led by BVF Partners, Logos Capital, and Vivo Capital
Series E (2024): $16.3M, investors not publicly disclosed
Key Investors in Delcath Systems
BVF Partners
BVF Partners L.P. is a San Francisco-based private investment partnership specializing in fundamentally-driven public biotechnology investments. Since its inception in 1993, BVF has strived to build concentrated, long-term investments in small-cap biotechnology companies while performing rigorous diligence and ongoing monitoring of its investments.
Logos Capital
Logos Capital is a Miami-based impact investment firm dedicated to providing financial solutions that address global challenges. Established in 2011, the firm offers services in investment banking, private equity, trade finance, and project finance, targeting companies with positive social and environmental impacts.
Vivo Capital
Vivo Capital founded in 1996 and headquartered in Palo Alto, California, is a global healthcare investment firm focused on private and public equity as well as venture capital.
What's next for Delcath Systems?
With the recent infusion of capital, Delcath Systems is expected to prioritize the expansion of its commercial footprint and the continued clinical validation of its delivery platform. The strategic focus will likely center on scaling the availability of the Delcath Hepatic CHEMOSAT Delivery System in key markets, alongside ongoing research and development efforts to optimize patient outcomes. As the company transitions into this next phase of growth, the focus remains on operational execution and the integration of its technology into standard clinical practice for liver cancer management. Investors will be monitoring the company's ability to translate this financial backing into sustained market penetration and improved clinical utility.
See full Delcath Systems company page
